OncoMatch/Clinical Trials/NCT06492408

Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

Is NCT06492408 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab for hepatic cancer.

Phase 2RecruitingSecond Affiliated Hospital of Guangzhou Medical UniversityNCT06492408Data as of May 2026

Treatment: ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab — This trial is designed to investigate the safety, response rates and survival outcomes of patients with hepatocellular carcinoma by delivery of CTLA4 and PD1 or PDL1 antibodies combination through CT-guided intra-tumor (IT) injection.

Check if I qualify

Extracted eligibility criteria

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: clinical trial therapy

Patients participated in clinical trials of equipment or drugs (signed informed consent) within 4 weeks

Cannot have received: any prior malignancy

Patients accompanied with other tumors or past medical history of malignancy

Lab requirements

Blood counts

ANC >= 1.5 x 10^9/L; Hemoglobin >= 8.0 g/dL; Platelets >= 100 x 10^9/L

Kidney function

Creatinine <= 1.5 x ULN or calculated creatinine clearance >= 50 mL/min using Cockcroft-Gault formula OR 24-hour urine creatinine clearance >= 50 mL/min

Liver function

Total bilirubin <= 1.5 x ULN (except subjects with Gilbert syndrome who can have total bilirubin < 3.0 mg/dL)

Absolute neutrophil count (ANC) >= 1.5 x 10^9/L; Hemoglobin >= 8.0 g/dL; Platelets >= 100 x 10^9/L; Total bilirubin <= 1.5 x upper limit of normal (ULN) (except subjects with Gilbert syndrome who can have total bilirubin < 3.0 mg/dL); Creatinine <= 1.5 x ULN or calculated creatinine clearance >= 50 mL/min using Cockcroft-Gault formula for creatinine clearance calculation OR 24-hour urine creatinine clearance >= 50 mL/min.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify